Alexander Erik K, Robinson Malcolm, Staniec Maryjane, Dluhy Robert G
Thyroid and Endocrine Divisions, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachussets, USA.
Clin Endocrinol (Oxf). 2002 Dec;57(6):827-31. doi: 10.1046/j.1365-2265.2002.01660.x.
Necrolytic migratory erythema (NME), the characteristic rash associated with the glucagonoma syndrome, is a cause of substantial morbidity among patients with this rare malignancy. Treatment options are suboptimal, and often useful for only short or moderate durations. We report the effective, long-term (> 1 year) use of intermittent infusions of amino acids (AA) and fatty acids (FA) administered via peripheral intravenous access for the treatment of NME in the glucagonoma syndrome. Despite resolution of the NME, serum amino acid (initially subnormal) and fatty acid (initially normal) levels remained unchanged. Tumour growth and other symptoms related to the glucagonoma syndrome appear unaffected by such infusions.
坏死性游走性红斑（NME）是与胰高血糖素瘤综合征相关的特征性皮疹，是这种罕见恶性肿瘤患者发病的一个重要原因。治疗选择并不理想，通常仅在短期或中期有效。我们报告了通过外周静脉通路间歇性输注氨基酸（AA）和脂肪酸（FA）用于治疗胰高血糖素瘤综合征中的NME的有效、长期（>1年）应用。尽管NME得到缓解，但血清氨基酸（最初低于正常）和脂肪酸（最初正常）水平保持不变。肿瘤生长和与胰高血糖素瘤综合征相关的其他症状似乎不受此类输注的影响。
